Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2

4(57.1%)

Phase 3

2(28.6%)

N/A

1(14.3%)

7Total

Phase 2(4)

Phase 3(2)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT03396068Phase 3Unknown

NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation

Role: collaborator

NCT03396601Phase 3Unknown

NRX100 vs. Placebo for Rapid Stabilization of Acute Suicidal Ideation and Behavior in Bipolar Depression

Role: collaborator

NCT03402152Phase 2Completed

NRX101 Glx Biomarker Validation Study

Role: collaborator

NCT02974010Phase 2Completed

Sequential Therapy for the Treatment of Severe Bipolar Depression.

Role: collaborator

NCT01907490Phase 2Completed

Safety and PK Study of Ha44 Gel Under Maximal Use Conditions for Treatment of Head Lice Infestation

Role: collaborator

NCT01831024Not ApplicableUnknown

Efficacy and Safety of Dignicap System for Preventing Chemotherapy Induced Alopecia

Role: lead

NCT01220206Phase 2Completed

POMx In the Treatment of Erectile Dysfunction

Role: collaborator

All 7 trials loaded